Cardioprotective Action of the JNK Inhibitor Tryptanthrin Oxime in the Late Period after Myocardial Infarction
- PMID: 39343845
- DOI: 10.1007/s10517-024-06241-6
Cardioprotective Action of the JNK Inhibitor Tryptanthrin Oxime in the Late Period after Myocardial Infarction
Abstract
In experiments on Wistar rats, the effect of a new selective JNK inhibitor tryptanthrin oxime (TR-Ox) on parameters of systemic hemodynamics, cardiohemodynamics, and post-infarction fibrosis was studied 4 months after acute myocardial ischemia (1 h) followed by reperfusion. TR-Ox was administered intraperitoneally at a dose of 12 mg/kg 20 min before reperfusion, and then once a day for the next 4 days. Administration of TR-Ox to animals in the acute phase of myocardial infarction contributed to more complete preservation of myocardial viability in the delayed period: a relative increase of muscle elements proportion in the scar, a decrease in the formation of connective tissue areas with complete and >50% replacement of the myocardium, and deceleration of fibrotic scarring in myocardium areas distant from the focus of injury, resulting in improved systolic and diastolic myocardial function. Four months after myocardial infarction, significant improvement in systemic hemodynamics and cardiohemodynamics parameters was observed in the group treated with TR-Ox: stroke volume, cardiac output, left ventricular systolic pressure, maximum rates of left ventricle pressure rise and fall significantly increased and the left ventricle end-diastolic pressure decreased in comparison with the corresponding parameters in the control group.
Keywords: fibrosis; heart failure; myocardial infarction; rats; tryptanthrin oxime.
© 2024. Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Effect of IQ-1 on the Infarct Size and the Parameters of Cardiodynamic Indicators in the Acute Period after Myocardial Ischemia/Reperfusion in Rats.Bull Exp Biol Med. 2024 Feb;176(4):447-451. doi: 10.1007/s10517-024-06044-9. Epub 2024 Mar 15. Bull Exp Biol Med. 2024. PMID: 38491254
-
Endothelin receptor antagonist BQ-123 ameliorates myocardial ischemic-reperfusion injury in rats: a hemodynamic, biochemical, histopathological and electron microscopic evidence.Biomed Pharmacother. 2010 Nov;64(9):639-46. doi: 10.1016/j.biopha.2010.06.001. Epub 2010 Jul 21. Biomed Pharmacother. 2010. PMID: 20888175
-
Comparative Evaluation of Neuroprotective Activity of Tryptanthrin and Its Oxime in Middle Cerebral Artery Occlusion in Rats.Bull Exp Biol Med. 2024 Jul;177(3):344-348. doi: 10.1007/s10517-024-06186-w. Epub 2024 Aug 10. Bull Exp Biol Med. 2024. PMID: 39126546
-
Cardioprotective effect of water and ethanol extract of Salvia miltiorrhiza in an experimental model of myocardial infarction.J Ethnopharmacol. 2012 Jan 31;139(2):440-6. doi: 10.1016/j.jep.2011.11.030. Epub 2011 Nov 26. J Ethnopharmacol. 2012. PMID: 22138518
-
Cardioprotective effects of memantine in myocardial ischemia: Ex vivo and in vivo studies.Eur J Pharmacol. 2020 Sep 5;882:173277. doi: 10.1016/j.ejphar.2020.173277. Epub 2020 Jun 13. Eur J Pharmacol. 2020. PMID: 32544502
References
-
- Writing Committee Members; Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS Jr, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM, Zwischenberger BA. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2022;79(2):e21-e129. https://doi.org/10.1016/j.jacc.2021.09.006
-
- Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart Failure With Reduced Ejection Fraction: A Review. JAMA. 2020;324(5):488-504. https://doi.org/10.1001/jama.2020.10262 - DOI - PubMed
-
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021;42(36):3599-3726. https://doi.org/10.1093/eurheartj/ehab368
-
- Swaroop G. Post-myocardial infarction heart failure: a review on management of drug therapies. Cureus. 2022;14(6):e25745. https://doi.org/10.7759/cureus.25745 - DOI - PubMed - PMC
-
- Li C, Li J, Xue K, Zhang J, Wang C, Zhang Q, Chen X, Gao C, Yu X, Sun L. MicroRNA-143-3p promotes human cardiac fibrosis via targeting sprouty3 after myocardial infarction. J. Mol. Cell. Cardiol. 2019;129:281-292. https://doi.org/10.1016/j.yjmcc.2019.03.005 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials